作者
Emanuel Della-Torre, Corrado Campochiaro, Giulio Cavalli, Giacomo De Luca, Angela Napolitano, Salvatore La Marca, Nicola Boffini, Valentina Da Prat, Gaetano Di Terlizzi, Marco Lanzillotta, Patrizia Rovere Querini, Annalisa Ruggeri, Giovanni Landoni, Moreno Tresoldi, Fabio Ciceri, ALberto Zangrillo, Francesco De Cobelli, Lorenzo Dagna
发表日期
2020/10/1
期刊
Annals of the rheumatic diseases
卷号
79
期号
10
页码范围
1277-1285
出版商
BMJ Publishing Group Ltd
简介
Objectives
To assess the safety and efficacy of interleukin (IL)−6 blockade with sarilumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation.
Methods
We conducted an open-label study of sarilumab in severe COVID-19 pneumonia (PaO2/FiO2 <300 mm Hg) with hyperinflammation (elevated inflammatory markers and serum IL-6 levels). Sarilumab 400 mg was administered intravenously in addition to standard of care and results were compared with contemporary matched patients treated with standard of care alone. Clinical improvement, mortality, safety and predictors of response were assessed at 28 days.
Results
Twenty-eight patients were treated with sarilumab and 28 contemporary patients receiving standard of care alone were used as controls. At day 28 of follow-up, 61% of patients treated with sarilumab experienced clinical improvement and 7% died. These findings were not …
学术搜索中的文章
E Della-Torre, C Campochiaro, G Cavalli, G De Luca… - Annals of the rheumatic diseases, 2020